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Abstract
Taurine participates in a number of different physiologic and biologic processes in the kidney, often reflected by
urinary excretion patterns. The kidney is key to aspects of taurine body pool size and homeostasis. This review will
examine the renal-taurine interactions relative to ion reabsorption; renal blood flow and renal vascular endothelial
function; antioxidant properties, especially in the glomerulus; and the role of taurine in ischemia and reperfusion
injury. In addition, taurine plays a role in the renal cell cycle and apoptosis, and functions as an osmolyte during
the stress response. The role of the kidney in adaptation to variations in dietary taurine intake and the regulation
of taurine body pool size are described. Finally, the protective function of taurine against several kidney diseases is
reviewed.
Introduction
The interactions between the kidney and taurine are
many and varied. Taurine participates in several biologic
processes in the kidney, and the kidney influences speci-
fic aspects of taurine homeostasis [1]. The numerous
physiologic regulators of taurine handling by the kidney
have been recently reviewed [2]. Thus, this review will
focus on several aspects of renal function in relation to
taurine and will cover large biologic themes. In addition,
the role of taurine in the pathophysiology of kidney dis-
ease will be examined.
The physiochemical properties of the ß-amino acid
taurine are probably responsible for some of its biologic
characteristics. It is readily soluble in aqueous solutions.
Taurine is not incorporated into protein, and can serve
as an intracellular osmolyte. The taurine molecule acts
as a zwitterion at physiologic pH and resides within the
cell in millimolar quantities. Its accumulation within the
cell requires active transport from the extracellular
environment, where it is found in only micromolar
quantities [3]. It has the lowest pK1 and pK2 of all
amino acids. Some of these properties lead to the role
of conjugation of bile acids [4] and uridine in tRNA [5].
Ion reabsorption
The active uphill transport of taurine occurs via a sodium-
dependent transporter (TauT) [6]. In addition to sodium,
taurine uptake by renal epithelia requires chloride or bro-
mide [7]. The model that best describes this transport is 2
Na+:1 taurine:1 Cl- (Figure 1). Sodium and chloride move
into cells by means of an external to internal downhill Na+
gradient (a chemical gradient), and then the sodium is
pumped out of the cell by Na+K+-dependent ATPase.
Taurine transport is stereospecific, inhibited by other
ß-amino acids and GABA (gamma-aminobutyric acid) but
not by a-amino acids, and is membrane surface-specific.
In a proximal tubule cell line (LLC-PK1), uptake is
maximal on the apical surface; in a distal tubule cell
line (MDCK), uptake occurs at the basolateral surface (Fig-
ure 2) [8].
Taurine efflux from renal cells is dependent on the
intracellular taurine concentration and requires the pre-
sence of both Na+ and Cl- in the system. It does not
contribute to the renal adaptive response described
below. Efflux is much slower than uptake and has a
higher Km. That taurine egress is dependent on specific
ions suggests that it is not purely passive diffusion, but
probably involves a carrier-facilitated process [9].
Taurine and its transporter also interact with glucose.
Taurine in the glomerular ultrafiltrate appears to blunt
the rate of Na+-dependent uptake of glucose by renal
tubules and can potentially lead to glucosuria. While it
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is tempting to assume that taurine molecules in the tub-
ular lumen compete for sodium and hence reduce
glucose uptake, the much higher concentration of glu-
cose (5.0 mM) makes this unlikely. Inhibition of the
Na+-independent glucose transporter 1 (GLUT1) in acti-
vated macrophages (RAW264.7 cells) by taurine chlora-
mine represents one mechanism by which inflammatory
cell function can be modulated [10]. Some form of allos-
teric competition between taurine and GLUT1 may be
relevant, but GLUT1 is commonly inhibited by vitamin
C [11] rather than by amino acids. Also, because taurine
is known to enhance insulin secretion [12], it may indir-
ectly enhance glucose entry into cells. Hence, taurine
may influence the intracellular as well as the transcellu-
lar movement of glucose.
Renal blood flow
Taurine has several effects on renal blood flow and
endothelial cell function. Sato et al. used the deoxycorti-
costerone acetate (DOCA)-salt rat model to study the
various vasoconstrictive and vasodilatory properties of
taurine [13]. Taurine status in the rat can influence
renal vascular resistance [14-16], autonomic nervous
control of arterial blood pressure [17,18] and the renal
response to high sugar intake-induced baroreceptor
reflex dysfunction [19]. Prenatal taurine exposure has
long-term effects on arterial blood pressure and renal
function in adult life.
Using the L-nitro-arginine methyl ester (L-NAME)
hypertension model in the rat, Hu et al. have shown
that taurine supplementation leads to increased serum
levels of nitric oxide (NO) and NO synthase activity
[14]. In addition, there is reduced renin-angiotensin-
aldosterone axis activity and blunted elevation of cyto-
kine and endothelin levels [14]. Taurine administration
also ameliorates hypertension in hypertension-prone
Kyoto rats [17].
Under certain circumstances, taurine depletion in fetal
or perinatal rats results in higher blood pressure in
adulthood [15,18-20]. Because of renal immaturity, and
the extremely high fractional excretion of taurine, much
of the taurine administered to rat pups is excreted in
the urine [21]. Hypothetically, this taurinuria could
result in volume depletion with a chronic up-regulation
of the renin-angiotensin system (RAS) [22]. Whether
this leads to imprinting and overactivity of the RAS is
unclear.
Taurine has been examined as a renoprotective agent
in several rat models [23-26]. The amino acid has been
shown to be renoprotective in both healthy and diseased
rats on salt- and fat-supplemented diets. If treated with
enalapril (to block the RAS) or taurine, both hyperten-
sive and glucose-intolerant rats will manifest a signifi-
cant reduction in urinary protein excretion. In addition,
rats fed high salt or high fat diets will excrete more
taurine, as do rats fed a high glucose diet. This tauri-
nuria may relate to competition for either sodium-
dependent transport processes, energy, or both.
Antioxidant properties
There exists extensive information regarding the antioxi-
dant properties of taurine and its derivatives [27-30]. For
this review, we will focus on studies relevant to the
renal system.
Trachtman et al. showed that culturing renal mesan-
gial cells in the presence of high glucose concentration
resulted in build-up of advanced glycosylation products
that could limit cell growth. Addition of the antioxi-
dants taurine and vitamin E reversed the growth
inhibition [29].
Figure 1 A model illustrates the 2 Na+:1 taurine:1 Cl- stoichiometry
of taurine transport.
Figure 2 Taurine transport is membrane surface-specific.
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The major mechanism of antioxidation is the reaction
of taurine with hypochlorous acid (HOCl) to form taur-
ine chloramine. In several models of glomerular disease
involving macrophage invasion there is increased intra-
cellular activity of myeloperoxidase to yield HOCl aris-
ing from H2O2 present in renal tissue. These reactive
oxygen species (ROS) can lead to DNA oxidation,
protein nitration, and lipid peroxidation of renal
cells [27,28,30]. Furthermore, oxidants arising from
puromycin- or adriamycin-induced renal injury in rats
are diminished following administration of 1% taurine in
the drinking water [29]. Taurine has also been asso-
ciated with reduction in oxidant levels in diabetic
nephropathy [31].
Ischemia/reperfusion injury
A model of renal injury that involves antioxidant injury
in the renal vessels is the renal ischemia/reperfusion
model. When rat kidney undergoes 60 min of ischemia
followed by 90 min reperfusion, there is a substantial
rise in serum creatinine and fall in renal ATP content.
Prior intravenous administration of taurine at 40 mg/kg
significantly reduces injury, as reflected by final serum
creatinine levels much lower than in control rats that
did not receive taurine [32]. No protection in terms of
ATP content was found. In a saphenous vein model,
ischemia reperfusion significantly reduced endothelial
cell survival by increasing both apoptosis and necrosis
[33]. These changes were accompanied by higher intra-
cellular ROS and calcium ions and a reduction in
endothelial nitric oxide synthase expression. Administra-
tion of taurine either prior to or following ischemia also
attenuated epithelial cell apoptosis and necrosis.
The addition of taurine to University of Wisconsin
(UW) solution was able to reduce tissue alterations dur-
ing hypoxia and reoxygenation and permitted recovery
of energy metabolism in LLC-PK1 cells [34]. However,
it is in hepatic tissue that taurine supplementation of
UW solution is more dramatic in tissue preservation
[32,34,35].
The most important role for taurine in oxidant injury
is probably the local and systemic scavenging of ROS.
Taurine chloramine has been shown to serve as an oxi-
dant reservoir, exhibiting delayed oxidant effects or
acting at a distant site [36]. This phenomenon is parti-
cularly noteworthy in phagocytes, which are a source of
taurine-related antioxidants [37] and are prevalent in an
early phase of inflammation in the glomerulus and
tubules [29].
Cell cycle and apoptosis
Evidence has emerged that taurine and its transporter,
the TauT protein, are important in the regulation of the
cell cycle and apoptosis of kidney cells [38]. Taurine
accumulates within the cells via active transport by
TauT, and, hence, the quantity of transporter protein in
the cell membrane determines intracellular b-amino
acid concentration [1]. Cisplatin, a nephrotoxic che-
motherapeutic agent, reduces taurine accumulation in
renal cells through a p53-dependent process in LLC-
PK1 cells [38]. In human embryonic kidney cells (293
cells), cisplatin up-regulates the proto-oncogene c-Jun.
These variable responses to the anti-tumor agent can be
shown by reporter assay and analysis, DNA binding, and
Western blots of taurine transporter protein in cells.
The functional TauT gene plays a modifying role in cis-
platin-induced renal injury, and the transcription rate
for TauT is regulated by p53 and c-Jun. The balance of
such regulation determines the rate of synthesis of
TauT protein, and thereby influences the fate of renal
cells.
The cell cycle-relevant pathway involving gene
expression of cyclin-c and the TauT gene is coopera-
tively regulated by renal cells in response to hyper-
tonicity [39] and reduced TauT promoter activity by
doxorubicin-induced activation of p53. This p53 acti-
vation can be seen in human fetal kidney cells (293)
and porcine proximal tubule cells (LLC-PK1), but in a
cell line devoid of p53 expression, [10](1) cells, there
is no repression of promoter [38]. With truncation of
the TauT promoter or with mutation of the p53 bind-
ing site there is no repression of TauT activity. Activa-
tion of the WT1 (Wilms tumor 1 gene) binding site in
the promoter region up-regulates TauT, as does c-Jun.
Figure 3 depicts the promoter region of TauT (3a)
and the details of the intracellular signaling that regu-
late the gene (3b). Among the binding sites in the pro-
moter region is a taurine response element (TREE) as
well as the proto-oncogenes previously mentioned
[1,2,38].
The product of TauT expression is TauT, a transpor-
ter protein containing 12 membrane-spanning domains
inserted into the apical or basolateral membranes of
renal cells. The taurine transporter has been cloned
from several species and tissues, including rat brain [6]
and dog kidney [40]. The genes encoding TauT in var-
ious species share a high degree of homology, residing
on chromosome 6 in the mouse and 3p21-25 in man
[41]. A renal adaptive response to taurine availability
has been demonstrated in many mammalian species,
including humans [42]. The mechanisms for this adap-
tive response, described in detail below, occur at the
levels of transcription, translation, and post-translational
modification [2]. Phosphorylation of serine 322 by pro-
tein kinase C (PKC) results in reduced transporter activ-
ity. This phosphorylation site is on the fourth
intracellular loop (S4), a highly conserved motif in all
mammalian species examined [6,40].
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Stress response and taurine as a renal osmolyte
Sorbitol, myo-inositol, betaine, a-glycerophosphorylcho-
line and taurine have been identified as major osmolytes
in the renal medulla [43-45]. The taurine uptake process
responds to osmolar signals under three special circum-
stances: 1) In fish adapting from fresh water to sea
water or vice versa [42,46,47]; 2) In the mammalian
brain under conditions of hyper- or hyponatremia
[48,49]; 3) In the unique osmolar environment of the
renal medulla [43-45,50]. Osmolar regulation results in
movement of taurine into or out of the medullary cell
rather than transcellular movement (reabsorption) (Fig-
ure 4). The renal medulla is the site of urinary concen-
tration or dilution, the countercurrent multiplier
mechanism, and aquaporin activity to form water chan-
nels. It can establish an osmolar gradient of 50 to 1200
mOsm in man, and even steeper gradients in rodents
[51]. Osmoregulation of taurine transport occurs in cells
of the loop of Henle and the medullary collecting duct.
The relevant biologic process is termed “cell volume
regulation” [44,45,52], (Figure 4). Several studies have
demonstrated that medullary cells in culture (MDCK or
M1 cells) exhibit taurine transport across the basolateral
surface rather than the apical surface [44,45,50]. A
response to hyperosmolarity is not evident in proximal
cell lines [50].
Handler and Kwon have shown that cells that respond
to hyperosmolar stress have a tonicity response element
(TonE) that responds to a TonE binding protein
(TonEBP) [44,53]. Extracellular sucrose or raffinose
leads to increased binding of TonEBP to TonE, up-regu-
lation of the genes for osmolar transporters (sorbitol,
myoinositol, etc.), increased production of mRNA for
TauT protein synthesis, export and insertion of protein
into the basolateral cell membrane, and enhanced trans-
port of taurine into the cell (Figure 5a) [44,50]. Ito et al.
have recently shown that the TonE site is located on the
promoter region proximal to -124 and distal to -99 (Fig-
ure 5b) [53]. A mutant TonE was unresponsive to
hypertonicity. This study also demonstrates how the
TonE/TonEBP system regulates cell volume and
prevents hyperosmolar stress [53].
Figure 3 (a) The promoter region of TauT contains important binding sites. (b) Details of the intracellular signaling that regulate the gene.
Figure 4 Taurine’s role as an osmolyte is shown by its net
movement under different conditions of tonicity.
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Renal regulation of taurine body pool size
Humans and other mammals on diets of differing taur-
ine or sulfur amino acid content excrete different
amounts of taurine, particularly as a percent of the fil-
tered load [2]. This is unusual because amino acid reab-
sorption by the kidney is highly efficient and generally
exceeds 99%. Urinary taurine excretion is low when
dietary taurine is restricted, as in a vegetarian diet. Con-
versely, when taurine intake is high, as in a diet rich in
meat and seafood, taurine excretion is high. Han et al.
review many of the specifics of this phenomenon [2].
Although renal regulation of ion reabsorption is a
long-recognized concept in transport physiology, appli-
cation of this principle to an amino acid is recent.
Examined in terms of the fractional excretion of taurine,
a variation of 0.5% to 80% has been found [54]. From a
renal physiologic viewpoint, both an increase and reduc-
tion of urinary excretion suggest an adaptive regulation
of transport, as is observed for the phosphate ion. We
use the term “renal adaptive response to alterations in
taurine intake” to describe these observations. Adapta-
tion of the taurine transporter system is a limited phe-
nomenon exhibited by the kidney and the gut, and
under conditions of malnutrition [2]. From a nutritional
perspective, all mammals should retain amino acids.
However, because taurine is a b-amino acid and is
devoid of a carboxyl group, it cannot be incorporated
into protein and resides freely in intracellular water.
Among other features is that taurine is not metabolized
by eukaryotes and does not contribute to gluconeogen-
esis, but it does participate in conjugation of certain
compounds (such as bile acids). It is largely inert and
not a source of energy. These ideal physiochemical
properties of taurine lead to a central hypothesis that
taurine can be responsible for cell volume regulation,
because taurine movement across the membrane surface
of a cell “can evoke changes in the concentration of
solutes and solvents within a cell” [52].
If taurine movement is important in the maintenance
of cell volume, what regulates the transport from a diet-
ary perspective? The transport of taurine in vivo appears
to be precisely regulated by the kidney, and is mimicked
in vitro in a variety of renal systems, including uptake
into renal slices, renal cells in culture, isolated renal
tubules, and isolated brush border membrane vesicles. It
is regulated at both the level of mRNA transcription
and protein synthesis [2].
The renal adaptive response was first described in
rats fed a low taurine diet (LTD, containing suboptimal
concentration of the precursor methionine), a normal
taurine diet (NTD), or a diet supplemented with 3%
(high) taurine (HTD) [54]. Specific taurine transporter
Figure 5 (a) Location of the TonE site on the TauT gene promoter region; (b) Model of TonE and TauT gene activity following exposure to
hypertonic conditions.
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mRNA levels are higher in LTD-fed rats and lower in
HTD-fed rats as compared to NTD-fed rats. Western
blot analysis shows more taurine transporter protein in
membranes from LTD-fed animals and less in those
fed HTD. The transcription rate is higher in cells in
culture deprived of taurine, and lower in cells exposed
to excess taurine [55-57]. Exposure of cells to b-ala-
nine, which depletes intracellular taurine, leads to
enhanced uptake. Likewise, in vivo, fasted rats show
higher taurine reabsorption rates and increased uptake
by brush border membrane vesicles [58]. Renal brush
border membrane vesicles prepared from kidneys of
taurine-deprived felines, who require dietary taurine to
maintain usual tissue levels, show greatly enhanced
taurine uptake [59]. This evidence indicates that what-
ever reduces intracellular taurine content up-regulates
the TauT gene and synthesis of TauT protein. Like-
wise, with increased taurine availability, increased diet-
ary intake and increased intracellular taurine
concentration, the uptake of taurine by vesicles and
cells is reduced and the process is down-regulated.
In an effort to clarify the signal for the up- or down-
regulation, truncation analysis of the promoter region
revealed that the taurine response element (TREE)
resides between the c-myb and p53 binding sites (Figure
3a). Truncation proximal to this site blocks the adaptive
response, as shown by reporter assay [2]. The molecule
that TREE responds to is not established, but it is
possible that it is the intracellular concentration of the
taurine molecule per se.
Plasma taurine levels do not vary greatly with the
availability of dietary taurine. Using specific antibodies,
taurine can be found in the nucleus, and thus is present
at the site of transcription. Addition of taurine to cell
cultures that have adapted to a low taurine environment
can rapidly (within 8 hr) reverse the up-regulation
response [8]. Both the rapid and the slower classic adap-
tive responses are found in numerous mammalian spe-
cies, including man, dog, pig and rodent. It is evident in
herbivores, carnivores and omnivores [2]. Depending on
taurine intake, the urinary fractional excretion of taurine
can vary from 0.5% to 80.0% (Figure 6).
The role of taurine in the pathophysiology of the kidney
Taurine has been shown to play a role in four different
forms of kidney disease: glomerulonephritis, diabetic
nephropathy, chronic renal failure, and acute kidney
injury (AKI). Much of the work on the role of taurine in
relation to kidney disease has been performed in animal
models, especially murine species. Many studies were
performed nearly two decades ago and are descriptive,
with the exception of the studies involving taurine
chloramine. Only in the area of protection of the kidney
against AKI have intracellular and molecular mechan-
isms been explored with the use of transgenic and
knockout mouse models and knockdown cell lines.
Figure 6 The renal adaptive response to dietary taurine intake conserves the total taurine body pool by reabsorbing or excreting taurine
depending on its availability.
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Protection against glomerulonephritis
Trachtman has reviewed the evidence that taurine func-
tions as a protective agent against immune- or toxicity-
induced forms of glomerulonephritis [29]. In the Masugi
glomerulonephritis model, rat kidney homogenates are
injected into rabbits. After several weeks, rabbit serum
is injected into rats. There occurs a heterologous phase
in which injected antibodies lead to the migration of
neutrophils into rat glomeruli. Myeloperoxidase (MPO)
located in neutrophils causes generation of radicals,
including hypochlorous acid [28,30,60,61]. Hypochlorous
acid activates tyrosine phosphorylation signal pathways,
leading to calcium signaling and tumor necrosis factor a
(TNFa) production [61]. In MPO-/- mice, fewer reac-
tants are generated [60].
Subsequently, in an autologous phase, T cells and
macrophages invade. The addition of taurine chloramine
to the diet appears to inhibit the function of antigen-
presenting cells and T cells in T cell-induced crescentic
glomerulonephritis [60]. Lian et al. showed that taurine
in drinking water reduced urinary protein excretion, and
both serum and urine platelet-activating factor (PAF)
levels [62]. Renal cortex and medulla PAF values are
also lower than in control rats.
Another component of glomerulonephritis is an
increase in glomerular albumin permeability (GAP). In a
model using isolated rat glomeruli, which are infiltrated
by neutrophils, H2O2 alone does not increase GAP, but
H2O2 and MPO together do increase GAP [63]. This
increase can be inhibited by superoxide dismutase, cata-
lase or taurine.
A model of chronic puromycin aminonucleoside
nephropathy that resembles human focal segmental glo-
merulosclerosis (FSGS) can be induced in rats. When
rats are given 1% (w/v) taurine in their drinking water,
urinary albumin excretion, segmental glomerulosclerosis
and tubulointerstitial injury are significantly diminished.
The urine albumin/creatinine ratio is lower in taurine-
supplemented animals, as are levels of the oxidant mal-
ondialdehyde in renal cortex. While the presumed
mechanism of nephroprotection is the formation of
taurine chloramine from taurine, this was not directly
measured [64].
Protection against diabetic nephropathy
Taurine has afforded renal protection against models of
diabetic nephropathy [31]. The importance of this
observation relates to the fact that diabetes mellitus
(type 1 and type 2) is the predominant cause of end
stage renal disease and the need for dialysis in North
America [65]. In rats with streptozocin-induced diabetic
nephropathy, addition of taurine to the drinking water
and exogenous insulin inhibited the increase in glomer-
ular planar area and ameliorated the condition, as did
vitamin E [31]. Administration of vitamin E and taurine
is associated with a reduction in advanced glycosylation
end products and the extent of lipid peroxidation. Taur-
ine can also neutralize the aldehydes of glycation end
products. The formation of Schiff’s base between taurine
and the aldehydes may diminish glucose toxicity. Taur-
ine and its congeners reduce the formation of intracellu-
lar oxidants and afford protection against erythrocyte
membrane damage [66], which could also reduce the
fragility of erythrocytes within glomerular capillaries.
Another hypothesis concerning the importance of
taurine in diabetic nephropathy involves the increased
production of sorbitol. Simply stated, the elevated extra-
cellular concentration of glucose disturbs cellular
osmoregulation and sorbitol is synthesized intracellularly
via the polyol pathway [67]. Intracellular accumulation
of sorbitol crowds out other intracellular osmolytes,
including taurine and myo-inositol. This disturbance of
cell volume regulation might be altered by taurine sup-
plementation, but this has not been tested [67].
Protection against chronic renal failure
In general, human patients with chronic renal failure
have reduced plasma and muscle intracellular concen-
trations of taurine [68]. However, an open label, non-
randomized trial of taurine supplementation (100 mg/
kg/day) in 10 hemodialysis patients resulted in extre-
mely high taurine levels in plasma and muscle [69]. The
plasma concentration rose from 50 μM to 712 – 2481
μM after 10 weeks of therapy, and muscle values more
than doubled [69], likely because no renal adaptive
response is possible in these patients and taurine cannot
be excreted. Clearance by dialysis was not measured.
Protection against acute kidney injury
Several models of AKI have been used to examine the
influence of taurine in this process. In a gentamicin
toxicity model, rats are injected with the aminoglycoside
antiobiotic, leading to a rise in serum creatinine and his-
tologic features of acute tubular necrosis. Administra-
tion of taurine attenuated the rise in creatinine and
there was less accumulation of gentamicin [70]. In this
model, the content of glutathione peroxidase and super-
oxide dismutase are similar in kidneys of taurine-treated
rats and controls.
Acute kidney injury is a major problem in patients
with sepsis, toxic injury and shock. The overall mortality
rate is approximately 50% [71]. In cancer patients
receiving chemotherapeutic agents, evidence of kidney
injury, as defined by elevation of biomarkers, is com-
mon. Cisplatin is a frequently used chemotherapeutic
agent, limited mainly by its nephrotoxicity. As many as
25% to 35% of patients experience a significant decline
in renal function after a single dose of cisplatin [72].
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Elevated expression of the tumor suppressor gene p53
has been detected in the kidneys of rats with cisplatin-
induced AKI [73]. Jiang et al. have shown that p53 is an
early signal in cisplatin-induced apoptosis in renal tubu-
lar cells [74]. These findings suggest that altered expres-
sion of distinct p53 target genes may be responsible for
p53-induced progressive renal failure.
Our studies have shown that TauT is negatively regu-
lated by p53 in renal cells [75]. Cisplatin, which stimu-
lates p53 production, accumulates in all cell types of the
nephron but is preferentially taken up by highly suscep-
tible cells in the S3 segment of the proximal tubule [76],
which is also the site where adaptive regulation of TauT
occurs [77]. Cisplatin has been shown to impair the
function of the taurine transporter and to down-regulate
expression of TauT at the transcriptional level in a
dose-dependent fashion [78]. We hypothesized that
TauT plays a role as an anti-apoptotic gene and func-
tions to protect renal cells from cisplatin-induced
nephrotoxicity in vivo.
Transgenic mice over-expressing human TauT and
wild-type mice were injected with cisplatin or saline;
renal failure biomarkers (blood urea nitrogen, creatinine,
urinary protein excretion) were measured and the mor-
tality rate recorded [78]. Over-expression of TauT
in the transgenic mice conferred significant protection
against renal damage and death caused by cisplatin as
compared to drug-treated control animals. Histological
analysis of kidneys from cisplatin-treated transgenic
mice showed greater amounts of membrane-bound
TauT protein, higher levels of intracellular taurine,
and less necrosis and apoptosis than the kidneys of cis-
platin-treated control mice. The histological findings
were similar to those found in saline-injected control
animals [38].
Physiologic roles for taurine relative to the kidney
It is possible to develop a structural-functional map of
the kidney based upon information presented in this
review. The nephron, the basic unit of the kidney, has
several different cell types that behave in a variety of
ways when interacting with taurine. The major charac-
teristics of taurine in terms of kidney function are
shown in Table 1. Although many of these roles may
overlap in different renal tissue types, the function of
each structural part sets the paradigm within which
taurine will operate.
The effect of taurine on renal blood vessels is to alter
blood flow, and probably to stabilize the endothelium of
the extensive renal vascular network [33]. Taurine influ-
ences blood flow within all types of vessels (capillaries,
venules and arterioles) through several mechanisms dis-
cussed previously, such as NO synthase activity, the
rheology of erythrocytes, the renin-angiotensin system
activity and vascular tone [15,16,24]. In the glomerulus,
where inflammatory cytokines evoke leukocyte migra-
tion, T cell activation, fibrosis, sclerosis and scarring,
the value of taurine as an antioxidant is paramount.
Taurine scavenges ROS that can influence podocyte
function and increase protein excretion. In the proximal
tubule, the site of bulk reabsorption of ions, organic
solutes and water, taurine influences sodium transport
and is taken up itself to maintain the body pool size in
an adaptive response to variations in dietary availability.
The taurine transporter system maintains the steep
plasma (extracellular, μM) to intracellular (mM) concen-
tration gradient despite huge variations in taurine
intake. In the medulla, taurine is critical to cell volume
regulation, moving into or out of collecting duct cells
relative to external osmolarity. Taurine’s role as an
osmolyte is likely important in many cell types in nearly
all organs, but it is especially evident in renal medullary
cells, where final urine concentration is established.
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